Feature | TCT | September 21, 2018

TCT 2018 Late-breaking Cardiovascular Clinical Trials

cardiologist Ted Feldman, M.D., at TCT 2017. #TCT2018 #TCT #TCT18 TCT Late breaking trials, studies.

October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clinical science presentations at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, which took place Sept. 21–25, 2018 at the San Diego Convention Center in California.

Every year, TCT features major medical research breakthroughs and highlights the latest data on the most innovative treatments that will impact patient care and how physicians treat heart disease, the leading cause of death in the world. The studies selected examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease.

 

Saturday, September 22, 2018

Late-Breaking Trials

IMPERIAL: A Randomized Trial of Drug-Eluting Stents for Treatment of Femoropopliteal Artery Lesions. Presented by William A. Gray

BIONYX: A Randomized Trial Evaluating an Ultra-Thin Strut Bioresorbable Polymer-Based Coronary Drug-Eluting Stent in an All-Comers Patient Population. Presented by Clemens von Birgelen

ReCre8: A Randomized Trial Evaluating a Polymer-Free Coronary Drug-Eluting Stent in an All-Comers Patient Population. Presented by Pieter R. Stella

LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy. Presented by Mitchell W. Krucoff

TALENT: A Randomized Trial Evaluating an Ultra-Thin Strut Bioresorbable Polymer-Based Coronary Drug-Eluting Stent in an All-Comers Patient Population. Presented by Patrick W. Serruys

• VIDEO: The Current State of Bioresorbable Stents in 2018 — Interview with Patrick Serruys, M.D.

SORT OUT IX: A Randomized Trial Comparing a Polymer-Free Coronary Drug-Eluting Stent With an Ultra-Thin Strut Bioresorbable Polymer-Based Drug-Eluting Stent in an All-Comers Patient Population. Presented by Lisette Okkels Jensen

 

Sunday, September 23, 2018

Late-breaking Trials

COAPT: A Randomized Trial of Transcatheter Mitral Valve Leaflet Approximation in Patients With Heart Failure and Secondary Mitral Regurgitation. Presented by Gregg W. Stone

COAPT VIDEO interview with co-principal investigator William Abraham

REDUCE-FMR: A Sham-Controlled Randomized Trial of Transcatheter Mitral Valve Indirect Annuloplasty in Patients With Heart Failure and Secondary Mitral Regurgitation. Presented by Horst Sievert

SOLVE-TAVI: A 2x2 Randomized Trial of Self-Expandable vs Balloon-Expandable Valves and General vs. Local Anesthesia in Patients Undergoing Transcatheter Aortic Valve Implantation. Presented by Holger Thiele

 

Late-breaking Clinical Science

PADN-5: A Randomized Trial of Pulmonary Artery Denervation in Patients With Combined Pre- and Postcapillary Pulmonary Hypertension. Presented by Shao-Liang Chen

PARTNER VALVE-IN-VALVE: Late Follow-up After Treatment of Failing Surgical Aortic Bioprosthetic Valves With a Balloon-Expandable Transcatheter Heart Valve. Presented by John G. Webb

Prosthesis-Patient Mismatch: Incidence, Predictors, and Outcome of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement. Presented by Howard C. Herrmann

TRIVALVE: Evaluation of Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation. Presented by Jörg Hausleiter

       

Monday, September 24, 2018

Late-breaking Trials

ULTIMATE: A Randomized Trial of Intravascular Ultrasound Guidance of Coronary Drug-Eluting Stent Implantation in an All-Comers Patient Population. Presented by Junjie Zhang

LRP: Assessment of Coronary Near-Infrared Spectroscopy Imaging to Detect Vulnerable Plaques and Vulnerable Patients. Presented by Ron Waksman

LRP Trial VIDEO interview with Waksman

OAC ALONE: A Randomized Trial of Oral Anticoagulation With vs Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation Beyond One Year After Drug-Eluting Stent Implantation. Presented by Yukiko Nakano

 

Late-breaking Clinical Science

FAST-FFR: Accuracy of Fractional Flow Reserve Derived From Coronary Angiography. Presented by William F. Fearon

SYNTAXES: Ten-Year Follow-up From a Randomized Trial of Drug-Eluting Stents vs Bypass Surgery in Patients With Left Main and Triple Vessel Disease. Presented by Daniel J.F.M. Thuijs

MAIN-COMPARE: Ten-Year Follow-up From a Nonrandomized Trial of Drug-Eluting Stents vs Bypass Surgery in Patients With Left Main Disease. Presented by Seung-Jung Park

PREPARE-CALC: A Randomized Trial of High-speed Rotational Atherectomy Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions. Presented by Gert Richardt

 

 

Tuesday, September 25, 2018

Late-Breaking Trials

ABSORB IV: A Blinded Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in an Expanded Patient Population Using Optimized Technique. Presented by Gregg W. Stone

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions. Presented by Pieter C. Smits

RADIOSOUND-HTN: A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension. Presented by Philipp Lurz

 

Late-Breaking Clinical Science

CorMicA: A Randomized Trial of Invasive Coronary Function Testing in Patients With Angina and Nonobstructive Coronary Artery Disease. Presented by Tom J. Ford

RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease. Presented by Hiroki Shiomi

NEOPRO: Nonrandomized Comparison of Two Transcatheter Heart Valve in Patients With Severe Aortic Stenosis. Presented by Matteo Pagnesi

PORTICO I: One-Year Outcomes With a Self-Expanding, Repositionable Transcatheter Heart Valve in Patients With Severe Aortic Stenosis. Presented by Lars Sondergaard

 

 

Additional TCT News and VIDEOS:

VIDEO: Editor’s Choice of the Most Innovative New Technology at TCT 2018

The Next Step in Bioresorbable Stent Technologies

VIDEO: The Importance of Ventricular Unloading in AMI and Cardiogenic Shock — Interview with Nevin Kapur, M.D.

VIDEO: How to Achieve Hemostasis With Large Bore Device Access — Interview with Philippe Genereux, M.D.

VIDEO: How to Reduce Cardiogenic Shock Mortality by 50 Percent — Interview with Babar Basir, D.O., and William O'Neill, M.D.

 

Reva Presents Key Data on its Bioresorbable Stents at TCT 2018

Amaranth Magnitude Bioresorbable Scaffold Shows Low MACE, Restenosis Rates at Nine Months

VIDEO: Comparison Between Watchman vs. Amulet LAA Occluders — Interview with Ashish Pershad, M.D.

VIDEO: Differences in Cardiac Complications and Presentation Between Men and Women — Interview with Cindy Grines, M.D.

BackBeat Cardiac Neuromodulation Therapy Reduces Blood Pressure at Two Years

 

VIDEO: Future Research and Development Efforts in Cardiovascular Medicine — Ian Meredith, MBBS, Ph.D., global CMO, Boston Scientific

VIDEO: Boston Scientific's Recent Cardiology Advances and Technology Acquisitions — Ian Meredith, MBBS, Ph.D., global CMO, Boston Scientific
 

 

 

 

Other Late-breaking Cardiology Trials in 2018:

ACC 2018 Late-Breaking Trials

EuroPCR 2018 Late-breaking Trials in Interventional Cardiology

Heart Rhythm 2018 Late-breaking Studies

SCAI 2018 Late-breaking Clinical Trials

 

 

For more information: www.crf.org, www.tctconference.com

 

#TCT #TCT2018 #TCT18


Related Content

News | Cardiovascular Clinical Studies

March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led ...

Home March 13, 2024
Home
News | Cardiovascular Clinical Studies

March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...

Home March 13, 2024
Home
News | Cardiovascular Clinical Studies

March 6, 2024 — Bodyport Inc., a biomarker-guided predictive care company focused on heart failure, announced data from ...

Home March 06, 2024
Home
News | Cardiovascular Clinical Studies

February 26, 2024 — More than 6 million Americans live with heart failure, and about half have an enlarged left ...

Home February 26, 2024
Home
News | Cardiovascular Clinical Studies

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
Home
News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
Home
Subscribe Now